Spheramine®: A Cell Therapeutic Approach to Parkinson's Disease

Modern Biopharmaceuticals: Design, Development and Optimization

Volumn 1, Issue , 2008, Pages 325-351

  Reissig, Elke ^a   Graf, Hermann ^a   Kapp, Friedrich Joachim ^a  

^a BAYER PHARMA AG   (Germany)

Author keywords

Dosing; Etiopathophysiology; Parkinson's disease; Putamen; Spheramine

Indexed keywords

EID: 84889958217     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9783527620982.ch14     Document Type: Chapter

References (68)

1. Coombs BD, Best A, Brown MS, Miller DE, Corboy J, Baier M, Simon JH. Multiple sclerosis pathology in the normal and abnormal appearing white matter of the corpus callosum by diffusion tensor imaging. Multiple Sclerosis 2004, 10, 392-397.
2. Calne DB, Mizuno Y. The neuromythology of Parkinson's Disease. Parkinsonism Relat Disord 2004, 10, 319-322.
3. Tanner CM. Is the cause of Parkinson's disease environmental or hereditary? Evidence from twin studies. Adv Neurol 2003, 91, 133-142.
4. Strickland D, Bertoni JM. Parkinson's prevalence estimated by a state registry. Mov Disord 2004, 19, 318-323.
5. Wooten GF, Currie LJ, Bovbjerg VE, Lee JK, Patrie J. Are men at greater risk for Parkinson's disease than women? J Neurol Neurosurg Psychiatry 2004, 75, 637-639.
6. Zhang ZX, Roman GC. Worldwide occurrence of Parkinson's disease: an updated review. Neuroepidemiology 1993, 12, 195-208.
7. de la Fuente-Fernandez R, Calne DB. Evidence for environmental causation of Parkinson's disease. Parkinsonism Relat Disord 2002, 8, 235-241.
8. Powers KM, Smith-Weller T, Franklin GM, Longstreth WT Jr, Swanson PD, Checkoway H. Parkinson's disease risks associated with dietary iron, manganese, and other nutrient intakes. Neurology 2003, 60, 1761-1766.
9. Greenamyre JT, Betarbet R, Sherer TB. The rotenone model of Parkinson's disease: genes, environment and mitochondria. Parkinsonism Relat Disord 2003, 9 (Suppl 2), S59-64.
10. Collier TJ, Steece-Collier K, Kordower JH. Primate models of Parkinson's disease. Exp Neurol 2003, 183, 258-262.
11. Muller T, Buttner T, Gholipour AF, Kuhn W. Coenzyme Q10 supplementation provides mild symptomatic benefit in patients with Parkinson's disease. Neurosci Lett 2003, 341, 201-204.
12. Chen H, Zhang SM, Hernan MA, Schwarzschild MA, Willett WC, Colditz GA, Speizer FE, Ascherio A. Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Arch Neurol 2003, 60, 1059-1064.
13. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003, 24, 197-211.
14. Przuntek H, Muller T, Riederer P. Diagnostic staging of Parkinson's disease: conceptual aspects. J Neural Transm 2004, 111, 201-216.
15. Jenner P. Oxidative stress in Parkinson's disease. Ann Neurol 2003, 53 (Suppl 3), S26-36.
16. Friedlander RM. Apoptosis and caspases in neurodegenerative diseases. N Engl J Med 2003, 348, 1365-1375.
17. Tieu K, Perier C, Vila M, Caspersen C, Zhang HP, Teismann P, Jackson-Lewis V, Stern DM, Yan SD, Przedborski S. L-3-hydroxyacyl-CoA dehydrogenase II protects in a model of Parkinson's disease. Ann Neurol 2004, 56, 51-60.
18. Shen J, Cookson MR. Mitochondria and dopamine; new insights into recessive parkinsonism. Neuron 2004, 43, 301-304.
19. Persad AS, Stedeford T, Tanaka S, Chen L, Banasik M. Parkinson's disease and CYP2D6 polymorphism in Asian populations: a metaanalysis. Neuroepidemiology 2003, 22, 357-361.
20. Nutt JG, Carter JH, Sexton GJ. The dopamine transporter: importance in Parkinson's disease. Ann Neurol 2004, 55, 766-773.
21. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K. α-Synuclein locus triplication causes Parkinson's disease. Science 2003, 302, 841.
22. Meredith GE, Halliday GM, Totterdell S. A critical review of the development and importance of proteinaceous aggregates in animal models of Parkinson's disease: new insights into Lewy body formation. Parkinsonism Relat Disord 2004, 10, 191-202.
23. Lohmann E, Periquet M, Bonifati V, Wood NW, De Michele G, Bonnet AM, Fraix V, Broussolle E, Horstink MW, Vidailhet M, Verpillat P, Gasser T, Nicholl D, Teive H, Raskin S, Rascol O, Destee A, Ruberg M, Gasparini F, Meco G, Agid Y, Durr A, Brice A, French Parkinson's Disease Genetics Study Group; European Consortium on Genetic Susceptibility in Parkinson's Disease. How much phenotypic variation can be attributed to parkin genotype? Ann Neurol 2003, 54, 176-185.
24. Farrer M, Chan P, Chen R, Tan L, Lincoln S, Hernandez D, Forno L, Gwinn-Hardy K, Petrucelli L, Hussey J, Singleton A, Tanner C, Hardy J, Langston JW. Lewy bodies and parkinsonism in families with parkin mutations. Ann Neurol 2001, 50, 293-300.
25. McNaught KS, Olanow CW. Proteolytic stress: a unifying concept for the etiopathogenesis of Parkinson's disease. Ann Neurol 2003, 53 (Suppl 3), S73-84.
26. McNaught KS, Perl DP, Brownell AL, Olanow CW. Systemic exposure to proteasome inhibi-tors causes a progressive model of Parkinson's disease. Ann Neurol 2004, 56, 149-162.
27. Hunot S, Hirsch EC. Neuroinflammatory processes in Parkinson's disease. Ann Neurol 2003, 53 (Suppl 3), S49-58.
28. Hartmann A, Hunot S, Hirsch EC. Inflammation and dopaminergic neuronal loss in Parkinson's disease: a complex matter. Exp Neurol 2003, 184, 561-564.
29. Ringheim GE, Conant K. Neurodegenerative disease and the neuroimmune axis (Alzheimer's and Parkinson's disease, and viral infections). J Neuroimmunol 2004, 147, 43-49.
30. Hornykiewicz O. Dopamine miracle: from brain homogenate to dopamine replacement. Mov Disord 2002, 17, 501-508.
31. Factor SA, Molho ES. Transient benefit of amantadine in Parkinson's disease: the facts about the myth. Mov Disord 1999, 14, 515-517.
32. Bonuccelli U. Comparing dopamine agonists in Parkinson's disease. Curr Opin Neurol 2003, 16 (Suppl 1), S13-19.
33. Schapira AH, Olanow CW. Neuroprotection in Parkinson disease: mysteries, myths, and misconceptions. J Am Med Ass 2004, 291, 358-364.
34. Nutt JG. Long-term L-DOPA therapy: challenges to our understanding and for the care of people with Parkinson's disease. Exp Neurol 2003, 184, 9-13.
35. Shulman LM. Levodopa toxicity in Parkinson disease: reality or myth? Reality - practice patterns should change. Arch Neurol 2000, 57, 406-407.
36. Metman LV, Gillespie M, Farmer C, Bibbiani F, Konitsiotis S, Morris M, Shill H, Bara-Jimenez W, Mouradian MM, Chase TN. Continuous transdermal dopaminergic stimulation in advanced Parkinson's disease. Clin Neuropharmacol 2001, 24, 163-169.
37. Linazasoro G. Recent failures of new potential symptomatic treatments for Parkinson's disease: causes and solutions. Mov Disord 2004, 19, 743-754.
38. de Bie RM, de Haan RJ, Schuurman PR, Esselink RA, Bosch DA, Speelman JD. Morbidity and mortality following pallidotomy in Parkinson's disease: a systematic review. Neurology 2002, 58, 1008-1012.
39. Okun MS, Vitek JL. Lesion therapy for Parkinson's disease and other movement disorders: update and controversies. Mov Disord 2004, 19, 375-389.
40. Kumar R, Lang AE, Rodriguez-Oroz MC, Lozano AM, Limousin P, Pollak P, Benabid AL, Guridi J, Ramos E, van der Linden C, Vandewalle A, Caemaert J, Lannoo E, van den Abbeele D, Vingerhoets G, Wolters M, Obeso JA. Deep brain stimulation of the globus pallidus pars interna in advanced Parkinson's disease. Neurology 2000, 55 (12 Suppl 6), S34-S39.
41. Kumar R, Lozano AM, Kim YJ, Hutchison WD, Sime E, Halket E, Lang AE. Double-blind evaluation of subthalamic nucleus deep brain stimulation in advanced Parkinson's disease. Neurology 1998, 51, 850-855.
42. Saint-Cyr JA, Trepanier LL, Kumar R, Lozano AM, Lang AE. Neuropsychological consequences of chronic bilateral stimulation of the subthalamic nucleus in Parkinson's disease. Brain 2000, 123, 2091-2108.
43. Freed CR, Greene PE, Breeze RE, Tsai WY, DuMouchel W, Kao R, Dillon S, Winfield H, Culver S, Trojanowski JQ, Eidelberg D, Fahn S. Transplantation of embryonic dopamine neurons for severe Parkinson's disease. N Engl J Med 2001, 344, 710-719.
44. Olanow CW, Goetz CG, Kordower JH, Stoessl AJ, Sossi V, Brin MF, Shannon KM, Nauert GM, Perl DP, Godbold J, Freeman TB. A double- blind controlled trial of bilateral fetal nigral transplantation in Parkinson's disease. Ann Neurol 2003, 54, 403-414.
45. Fink JS, Schumacher JM, Ellias SL, Palmer EP, Saint-Hilaire M, Shannon K, Penn R, Starr P, VanHorne C, Kott HS, Dempsey PK, Fischman AJ, Raineri R, Manhart C, Dinsmore J, Isacson O. Porcine xenografts in Parkinson's disease and Huntington's disease patients: preliminary results. Cell Transplant 2000, 9, 273-278.
46. Drucker-Colin R, Verdugo-Diaz L. Cell transplantation for Parkinson's disease: present status. Cell Mol Neurobiol 2004, 24, 301-316.
47. Dismore J, Ratliff J, Deacon T, Pakzaban P, Jacoby G, Galpern W, Isacson O. Embryonic stem cells differentiated in vitro as a novel source for transplantation. Cell Transplant 1996, 5, 131-143.
48. Thomson JA, Odorico JS. Human embryonic stem cells and embryonic germ cell lines. Trends Biotechnol 2000, 18, 53-57.
49. Buzanska L, Machaj EK, Zablocka B, Podja Z, Domanska-Janik K. Human cord blood-derived cells attain neuronal and glial features. J Cell Sci 2002, 115, 2131-2138.
50. Kim JH, Auerbach JM, Rodriguez-Gomez JA, Velasco I, Gvin D, Lumelsky N, Lee SH, Nguyen J, Sanchez-Pernaute R, Bankiewicz K, McKay RDG. Dopamine neurons from embryonic stem cells function in an animal model of Parkinson's disease. Nature 2002, 418, 50-56.
51. Studer L, Tabar V, McKay RDG. Transplantation of mesencephalic precursors leads to recovery of Parkinsonian rats. Nat Neurosci 1998, 1, 290-295.
52. Song HJ, Stevens CF, Gage FH. Neural stem cells from the hippocampus develop essential properties of functional CNS neurons. Nat Neurosci 2002, 5, 438-445.
53. Kondziolka D, Wechsler L, Goldstein S, Meltzer C, Thulborn KR, Gebel J, Janetta P, DeCesare S, Elder EM, McGrogan M, Reitman MA, Bynum L. Transplantation of cultured human neuronal cells for patients with stroke. Neurology 2000, 55, 565-569.
54. Barker RA. Repairing the brain in Parkinson's disease: where next? Mov Disord 2002, 17, 233-241.
55. McKay RD. Stem cell biology and neurodegenerative disease. Philos Trans R Soc Lond B Biol Sci 2004, 359, 851-856.
56. Porena M, Parziani S, Costantini E, Vespasiani G, Micali F. Autologous adrenal medullary transplant in Parkinson's disease: critical review of our results in 13 patients. Neurourol Urodyn 1996, 15, 195-201.
57. Rafael H. Autotransplantation of human carotid body cell aggregates for treatment of Parkinson's disease. Neurosurgery 2004, 54, 1035-1036.
58. Arjona V, Minguez-Castellanos A, Montoro RJ, Ortega A, Escamilla F, Toledo-Aral JJ, Pardal R, Mendez-Ferrer S, Martin JM, Perez M, Katati MJ, Valencia E, Garcia T, Lopez-Barneo J. Autotransplantation of human carotid body cell aggregates for treatment of Parkinson's disease. Neurosurgery 2003, 53, 321-328.
59. Hurelbrink CB, Barker RA. The potential of GDNF as a treatment for Parkinson's disease. Exp Neurol 2004, 185, 1-6.
60. Palfi S, Leventhal L, Chu Y, Ma SY, Emborg M, Bakay R, Deglon N, Hantraye P, Aebischer P, Kordower JH. Lentivirally delivered glial cell line-derived neurotrophic factor increases the number of striatal dopaminergic neurons in primate models of nigrostriatal degeneration. J Neurosci 2002, 22, 4942-4954.
61. Nutt JG, Burchiel KJ, Comella CL, Jankovic J, Lang AE, Laws ER Jr, Lozano AM, Penn RD, Simpson RK Jr, Stacy M, Wooten GF; ICV GDNF Study Group. Randomized, doubleblind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003, 60, 69-73.
62. Chase T. The significance of continuous dopaminergic stimulation in the treatment of Parkinson's disease. Drugs 1998, 55 (Suppl 1), 1-9.
63. Marmor MF, Wolfensberger TJ. The Retinal Pigment Epithelium: Function and Disease. Oxford University Press, New York, 1998.
64. Goetz CG, Stebbins GT, Blasucci LM. Differential progression of motor impairment in levodopa- treated Parkinson's disease. Mov Disord 2000, 15, 479-484.
65. Nutt JG, Carter JH, Lea ES, Sexton GJ. Evolution of the response to levodopa during the first 4 years of therapy. Ann Neurol 2002, 51, 686-693.
66. Macklin R. The ethical problems with sham surgery in clinical research. N Engl J Med 1999, 341, 992-996.
67. Freeman TB, Vawter DE, Leaverton PE, Godbold JH, Hauser RA, Goetz CG, Olanow CW. Use of placebo surgery in controlled trials of a cellular-based therapy for Parkinson's disease. N Engl J Med 1999, 341, 988-992.
68. Defer GL, Widner H, Marie RM, Remy P, Levivier M. Core assessment program for surgical interventional therapies in Parkinson's disease (CAPSIT-PD). Mov Disord 1999, 14, 572-584.